Peptides / MOTS-c / Australia

MOTS-c in Australia

Legal status, what it is, and the listed suppliers in Australia that list it.

Legal status in Australia

Not an approved medicine. Not listed by name in the Poisons Standard (June 2026).

As understood at 2026-09-22. Verify with the TGA.

What MOTS-c is

MOTS-c is a 16-amino-acid peptide encoded not in the cell nucleus but inside the mitochondrial genome, in the 12S rRNA region. It was identified in 2015. It occurs naturally in tissue and in blood, and the reviewed literature reports that circulating levels fall with age. The synthetic version sold by suppliers is a copy of that natural peptide.

Full MOTS-c page: targets and research →

Clinical Research

The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
Lee C, Zeng J, Drew BG, et al. (2015). Cell Metabolism. animal cell culture, then mice (age-related and high-fat-diet models of insulin resistance)
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds JC, Lai RW, Woodhead JST, et al. (2021). Nature Communications. animal young, middle-aged and old mice, plus measurement of MOTS-c in human skeletal muscle and blood after exercise
The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress
Kim KH, Son JM, Benayoun BA, Lee C (2018). Cell Metabolism. in-vitro cultured cells under glucose restriction and other metabolic stress
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Zheng Y, Wei Z, Wang T (2023). Frontiers in Endocrinology. review n/a (narrative review)